STOCK TITAN

Algernon Pharmac - AGNPF STOCK NEWS

Welcome to our dedicated page for Algernon Pharmac news (Ticker: AGNPF), a resource for investors and traders seeking the latest updates and insights on Algernon Pharmac stock.

Algernon Pharmaceuticals Inc. (symbol: AGNPF) is a Canadian clinical stage pharmaceutical development company dedicated to advancing treatments for unmet global medical needs. The company operates multiple research programs targeting chronic kidney disease, chronic cough, and non-alcoholic steatohepatitis (NASH). Algernon is also the parent company of Algernon NeuroScience, a subsidiary focused on the investigation of a proprietary form of psychedelic DMT for stroke and traumatic brain injury.

Recently, Algernon has achieved significant milestones, such as receiving a notice of intention to grant a patent from the Chinese Patent Office for its antifibrotic drug candidate NP-251 (Repirinast). This patent, which will be valid through 2038, enhances the global protection of the company's intellectual property. Another notable development includes the sale of its NP-120 (Ifenprodil) research program to Seyltx Inc. for USD $2 million and a 20% equity stake in Seyltx. Ifenprodil targets chronic cough by inhibiting NMDA receptors, and Seyltx is set to advance it through a Phase 2b clinical trial.

Algernon is also making strides with its DMT stroke research program under Algernon NeuroScience. The company plans to proceed with a Phase 2a study investigating the neuroplasticity effects of DMT in stroke patients. This program represents a pioneering effort to explore the potential of psychedelics in promoting brain recovery post-stroke.

Financially, Algernon has secured multiple patents in various markets, including Japan, Canada, Europe, and the United States, for its lead candidates. The company's forward-looking strategy involves robust intellectual property protection, strategic partnerships, and focused clinical trials.

In addition to its clinical advancements, Algernon has engaged ICP Securities Inc. for automated market making services to enhance liquidity and market presence. The company actively communicates with investors and stakeholders, as evidenced by planned special CEO interviews and Q&A sessions.

Algernon Pharmaceuticals is committed to developing effective treatments through rigorous research and strategic collaborations, positioning itself as a leader in innovative pharmaceutical solutions.

Rhea-AI Summary
Algernon Pharmaceuticals Inc. announces completion of feasibility study and finalization of clinical trial design for Phase 2 DMT Stroke study. The study will investigate the use of DMT for the treatment of stroke and its ability to promote neuroplasticity in brain injuries. The decision to investigate DMT for stroke treatment was based on a ground-breaking rat occlusion stroke study that showed DMT reduced infarct volume and led to full recovery of motor function. The Phase 2 study will focus on safety and measures of efficacy including preservation of brain tissue, motor recovery, depression, and biomarkers linked to stroke pathophysiology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.67%
Tags
-
Rhea-AI Summary
Algernon Pharmaceuticals announces non-brokered private placement for gross proceeds of CDN$205,000. Each unit consists of one common share and one common share purchase warrant. The offering is expected to close on July 21, 2023. The company will use the proceeds for working capital purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.21%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.9%
Tags
conferences clinical trial
-
Rhea-AI Summary
Algernon Pharmaceuticals' subsidiary, Algernon NeuroScience, has completed dosing of the third and final cohort in its Phase 1 study of an intravenous formulation of AP-188 (DMT). The highest dose maintained plasma DMT concentrations at targeted levels without safety issues. The company plans to publish the data and move on to a Phase 2 study for stroke and traumatic brain injury.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.27%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.89%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.97%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.11%
Tags
none
-
Rhea-AI Summary

Algernon Pharmaceuticals Inc. has received a Notice of Allowance from the USPTO for its patent application 17/258,402, which pertains to the treatment of Non-Alcoholic Steatohepatitis (NASH) using its lead drug, NP-251 (Repirinast). This significant allowance covers compositions and methods for treating non-alcohol fatty liver disease, supported by data showing Repirinast reduced hepatic fibrosis by 57% and NAFLD scores significantly. The company emphasizes that Repirinast is also a candidate for chronic kidney disease due to its efficacy in reducing fibrosis. In addition, Algernon aims to protect its intellectual property through international patent applications. This is a milestone for Algernon's drug repurposing program, according to CEO Christopher J. Moreau.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.62%
Tags
none
Rhea-AI Summary

Algernon Pharmaceuticals has completed dosing the second cohort in its Phase 1 clinical study of an intravenous DMT formulation, AP-188. The study aims to assess safety, tolerability, and pharmacokinetics of DMT when administered via prolonged infusion. Following safety review committee approval, the final cohort will begin dosing soon. The study plans to include up to 60 volunteers, both experienced and inexperienced with psychedelics. The company is also collaborating with experts to prepare for Phase 2 trials aimed at treating brain injuries. Algernon has patented new formulations of DMT for potential stroke-related applications.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags

FAQ

What is the current stock price of Algernon Pharmac (AGNPF)?

The current stock price of Algernon Pharmac (AGNPF) is $0.07 as of February 21, 2025.

What is the market cap of Algernon Pharmac (AGNPF)?

The market cap of Algernon Pharmac (AGNPF) is approximately 1.7M.

What is Algernon Pharmaceuticals Inc.'s main focus?

Algernon Pharmaceuticals Inc. focuses on developing treatments for chronic kidney disease, chronic cough, and investigating DMT for stroke and traumatic brain injury.

What recent achievements has Algernon Pharmaceuticals Inc. made?

Algernon recently received a notice of intention to grant a patent for NP-251 in China and sold its Ifenprodil program to Seyltx Inc. for $2 million and a 20% equity stake.

What is the significance of Repirinast for Algernon Pharmaceuticals?

Repirinast is Algernon's lead candidate for treating chronic kidney disease, showing significant reduction in fibrosis and benefiting from patents in multiple countries.

How is Algernon advancing its DMT stroke research program?

Algernon plans to conduct a Phase 2a study to investigate the effects of DMT on neuroplasticity in stroke patients, aiming to promote brain recovery.

What partnerships does Algernon Pharmaceuticals Inc. have?

Algernon has partnered with companies like Seyltx Inc. and ICP Securities Inc. for various strategic initiatives, including the sale of research programs and market making services.

What are the key areas of research for Algernon NeuroScience?

Algernon NeuroScience is focused on investigating psychedelic DMT for stroke and traumatic brain injury, particularly its potential to promote neuroplasticity.

What financial strategies does Algernon Pharmaceuticals pursue?

Algernon secures patents globally for its lead candidates, engages in strategic partnerships, and ensures liquidity through services like those provided by ICP Securities Inc.

What is Ifenprodil and its potential impact?

Ifenprodil is an NMDA receptor antagonist targeting chronic cough. It has shown promising results in reducing cough counts, especially in difficult-to-treat populations.

How does Algernon Pharmaceuticals engage with its investors?

Algernon actively communicates with its investors through CEO interviews, Q&A sessions, and regular updates on clinical advancements and strategic developments.

What is the significance of Algernon's recent market making agreement?

The agreement with ICP Securities Inc. aims to enhance the liquidity and market presence of Algernon's shares, correcting temporary imbalances in supply and demand.
Algernon Pharmac

OTC:AGNPF

AGNPF Rankings

AGNPF Stock Data

1.70M
22.32M
16.76%
16.49%
Biotechnology
Healthcare
Link
Canada
Vancouver